Alhadab, Ali A.
30  Ergebnisse:
Personensuche X
?
1

Case–control matching‐guided exposure‐efficacy relationship..:

Soltantabar, Pooneh ; Alhadab, Ali ; Hibma, Jennifer...
CPT: Pharmacometrics & Systems Pharmacology.  12 (2023)  12 - p. 2001-2012 , 2023
 
?
2

Analysis of US Food and Drug Administration Oncology Approv..:

Yang, Derek Z. ; Alhadab, Ali ; Parivar, Kourosh..
Clinical Pharmacology & Therapeutics.  112 (2021)  4 - p. 782-790 , 2021
 
?
3

Physiologically‐Based Pharmacokinetic Model of Sertraline i..:

Alhadab, Ali A. ; Brundage, Richard C.
Clinical Pharmacology & Therapeutics.  108 (2020)  1 - p. 136-144 , 2020
 
?
 
?
6

Pharmacokinetics-pharmacodynamics of sertraline as an antif..:

ASTRO-CM Study Team ; Alhadab, Ali A. ; Rhein, Joshua...
Journal of Pharmacokinetics and Pharmacodynamics.  46 (2019)  6 - p. 565-576 , 2019
 
?
 
?
8

Subcutaneous amivantamab (ami) in patients (pts) with advan..:

Minchom, Anna ; Krebs, Matthew ; Cho, Byoung...
Minchom , A , Krebs , M , Cho , B , Lee , S-H , Leighl , N , O'Neil , B , Sabari , J , Kudgus-Lokken , R , Alhadab , A , Haddish-Berhane , N , Zemlickis , D , Mitselos , A , Berkay , E , Bauml , J , Knoblauch , R , Hellemans , P & Johnson , M 2023 , ' Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose. ' , Journal of Clinical Oncology , vol. 41 , no. 16_suppl , pp. 9126-9126 . https://doi.org/10.1200/JCO.2023.41.16_suppl.9126.  , 2023
 
?
 
1-15